Arda Therapeutics is pioneering the use of targeted cell depletion to treat chronic diseases. By identifying and selectively depleting pathogenic cells, Arda aims to develop therapies that offer greater efficacy, faster discovery timelines and reduced dosing frequency compared to traditional approaches. With a world-class team and a robust pipeline, Arda is poised to transform the landscape of chronic disease treatment.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 10/09/24 | $43,000,000 | Series A |
Alumni Ventures Group Andreessen Horowitz  Biovision Ventures Eli Lilly and Company ExitFund Gaingels GV Indicator Ventures LifeLink Ventures Mana Ventures RV Invest Two Sigma Ventures Valhalla Partners | undisclosed |
